BSE Live
Nov 14, 13:51Prev. Close
1234.55
Open Price
1241.30
Bid Price (Qty.)
1244.05 (35)
Offer Price (Qty.)
1245.00 (31)
NSE Live
Nov 14, 13:51Prev. Close
1234.90
Open Price
1235.20
Bid Price (Qty.)
1244.60 (67)
Offer Price (Qty.)
1244.80 (18)
| Key Financial Ratios of Dr Reddys Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 67.89 | 335.22 | 271.47 | 131.57 | 117.67 | |
| Diluted EPS (Rs.) | 67.79 | 334.59 | 270.90 | 131.21 | 117.34 | |
| Cash EPS (Rs.) | 88.82 | 421.65 | 343.37 | 196.96 | 188.25 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 402.27 | 1,693.93 | 1,397.73 | 1,154.59 | 1,060.20 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 402.27 | 1,693.93 | 1,397.73 | 1,154.59 | 1,060.20 | |
| Revenue from Operations/Share (Rs.) | 391.41 | 1,679.32 | 1,480.77 | 1,294.78 | 1,144.68 | |
| PBDIT/Share (Rs.) | 115.64 | 529.22 | 444.45 | 255.53 | 250.08 | |
| PBIT/Share (Rs.) | 95.21 | 441.09 | 369.41 | 185.51 | 176.23 | |
| PBT/Share (Rs.) | 91.82 | 430.83 | 360.83 | 179.75 | 170.40 | |
| Net Profit/Share (Rs.) | 68.39 | 333.53 | 268.33 | 126.94 | 114.40 | |
| NP After MI And SOA / Share (Rs.) | 67.81 | 334.41 | 270.55 | 131.16 | 117.28 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 29.54 | 31.51 | 30.01 | 19.73 | 21.84 | |
| PBIT Margin (%) | 24.32 | 26.26 | 24.94 | 14.32 | 15.39 | |
| PBT Margin (%) | 23.45 | 25.65 | 24.36 | 13.88 | 14.88 | |
| Net Profit Margin (%) | 17.47 | 19.86 | 18.12 | 9.80 | 9.99 | |
| NP After MI And SOA Margin (%) | 17.32 | 19.91 | 18.27 | 10.12 | 10.24 | |
| Return on Networth/Equity (%) | 16.85 | 19.74 | 19.35 | 11.35 | 11.06 | |
| Return on Capital Employed (%) | 21.81 | 25.13 | 25.95 | 15.44 | 15.84 | |
| Return on Assets (%) | 11.44 | 14.35 | 13.96 | 7.33 | 7.33 | |
| Total Debt/Equity (X) | 0.12 | 0.06 | 0.05 | 0.16 | 0.15 | |
| Asset Turnover Ratio (%) | 0.74 | 0.79 | 0.80 | 0.56 | 0.60 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.92 | 2.59 | 2.38 | 1.82 | 1.80 | |
| Quick Ratio (X) | 1.37 | 1.92 | 1.82 | 1.30 | 1.24 | |
| Inventory Turnover Ratio (X) | 0.84 | 0.80 | 0.85 | 0.86 | 1.03 | |
| Dividend Payout Ratio (NP) (%) | 11.78 | 11.91 | 11.04 | 18.99 | 21.24 | |
| Dividend Payout Ratio (CP) (%) | 9.05 | 9.43 | 8.64 | 12.38 | 13.03 | |
| Earnings Retention Ratio (%) | 88.22 | 88.09 | 88.96 | 81.01 | 78.76 | |
| Cash Earnings Retention Ratio (%) | 90.95 | 90.57 | 91.36 | 87.62 | 86.97 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 34.09 | 51.59 | 51.85 | 44.39 | 42.90 | |
| Interest Coverage Ratios (Post Tax) (%) | 34.09 | 51.59 | 51.85 | 44.39 | 42.90 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 97,515.87 | 102,592.50 | 76,382.99 | 72,310.86 | 75,755.28 | |
| EV/Net Operating Revenue (X) | 2.99 | 3.66 | 3.10 | 3.36 | 3.98 | |
| EV/EBITDA (X) | 10.11 | 11.62 | 10.32 | 17.01 | 18.20 | |
| MarketCap/Net Operating Revenue (X) | 2.92 | 3.67 | 3.12 | 3.33 | 3.94 | |
| Retention Ratios (%) | 88.21 | 88.08 | 88.95 | 81.00 | 78.75 | |
| Price/BV (X) | 2.84 | 3.63 | 3.31 | 3.73 | 4.26 | |
| Price/Net Operating Revenue | 2.92 | 3.67 | 3.12 | 3.33 | 3.94 | |
| Earnings Yield | 0.06 | 0.05 | 0.06 | 0.03 | 0.03 |
11.11.2025
30.10.2025
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz